Drug

Oncology Update: regorafenib improves survival in metastatic colorectal cancer (mCRC)

According to a press release issued by Onyx Pharmaceuticals, Inc. on October 25, 2011 a Phase 3 trial with regorafenib in metastatic colorectal cancer (mCRC) patients  being conducted by Bayer HealthCare Pharmaceuticals met its primary endpoint of improved overall survival.   Apparently, this trial’s independent Data Monitoring Committee... Read more of this article

Oncology Update: ADCETRIS(TM) Brentuximab Vedotin

We have completed our preliminary assessment of the FDA approved oncology drug ADCETRIS (TM) Brentuximab Vedotin using BioHorizon’s proprietary assessment methodology and have designated this oncology therapeutic agent as High Impact.  Given the observed treatment effect in pivotal clinical trials we see potential for rapid uptake by oncologists responsible... Read more of this article

Amylin, Lilly, and Alkermes Await FDA Decision on Byetta for Diabetes

On February 25th, 2010, Amylin, Lilly, and Alkermes announced in a press release that the FDA had set March 12th 2010 as the Prescription Drug User Fee Act (PDUFA) action date for Byetta’s long acting formulation –  exenatide once weekly.   Our readers will recall that Byetta is used by type 2 diabetics for glycemic (blood glucose)... Read more of this article